2,4-二氟-3-甲基苯腈 | 847502-87-8

• 物质功能分类: 有机原料 - 有机氟化合物 - 氟苯腈系列
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2,4-二氟-3-甲基苯腈
• 中文别名: 2,6-二氟-3-氰基甲苯；2,4-二氟-3-甲基苯甲腈
• 英文名称: 2,4-difluoro-3-methylbenzonitrile
• CAS: 847502-87-8
• 化学式: C₈H₅F₂N
• mdl: MFCD07777155
• 分子量: 153.131
• InChiKey: GNNHZCHETSTMOG-UHFFFAOYSA-N

物化性质

• 熔点：
  42-45°C
• 沸点：
  212℃
• 密度：
  1.21
• 闪点：
  82℃
• 稳定性/保质期：
  按规定使用和贮存时不会分解，避免接触氧化物。

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.125
• 拓扑面积：
  23.8
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 危险等级：
  6.1
• 海关编码：
  2926909090
• 包装等级：
  III
• 危险类别：
  6.1
• 危险品运输编号：
  UN3439
• 危险性防范说明：
  P261,P280,P305+P351+P338,P311
• 危险性描述：
  H302+H312,H315,H319,H331,H335
• 储存条件：
  存放在密闭、阴凉、干燥的地方

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
2,4-Difluoro-3-methylbenzonitrile
Product Name:
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H311: Toxic in contact with skin
H302: Harmful if swallowed
H332: Harmful if inhaled
H315: Causes skin irritation
Causes serious eye irritation
H319:
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing
P309: IF exposed or you feel unwell:
P310: Immediately call a POISON CENTER or doctor/physician

---

Section 3. Composition/information on ingredients.
2,4-Difluoro-3-methylbenzonitrile
Ingredient name:
CAS number: 847502-87-8

---

Section 4. First aid measures
Immediately wash skin with copious amounts of water for at least 15 minutes while removing
Skin contact:
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.
Ingestion:

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C8H5F2N
Molecular weight: 153.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen fluoride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
UN Number: UN3439 Class: 6.1 Packing group: III
Proper shipping name: NITRILES, TOXIC, SOLID, N.O.S. (2,4-Difluoro-3-methylbenzonitrile)

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2,4-二氟-3-甲基苯腈 在 sodium hydride 、 三氟乙酸 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 、 mineral oil 为溶剂， 反应 25.58h， 生成 methyl 2-(4-cyano-3-fluoro-2-methylphenyl)acetate
  参考文献：
  名称：

  INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL

  摘要：

  公开号：

  EP2632465B1
• 作为产物：
  描述：

  3-溴-2,6-二氟甲苯 、 氰化亚铜 在 copper(l) iodide 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 18.0h， 生成 2,4-二氟-3-甲基苯腈
  参考文献：
  名称：

  Difluoroalkylaromatics

  摘要：

  本发明涉及3,4-二氟-2-烷基芳烃和2,4-二氟-3-烷基芳烃，涉及它们的制备方法以及它们用于制备活性成分的应用。

  公开号：

  US20050054733A1

文献信息

• [EN] SMALL MOLECULE INHIBITORS OF DIHYDROFOLATE REDUCTASE<br/>[FR] INHIBITEURS À PETITES MOLÉCULES DE LA DIHYDROFOLATE RÉDUCTASE
  申请人：CIDARA THERAPEUTICS INC

  公开号：WO2016201219A1

  公开（公告）日：2016-12-15

  The disclosure relates to compositions and methods for the treatment of fungal, bacterial, and parasitic infections and inhibition of fungal, bacterial, and parasitic growth. In particular, such compositions include dihydrofolate reductase (DHFR) inhibitors that are able to bind to DHFR and inhibit its function, resulting in inhibition of DNA biosynthesis and reduced cell division. The disclosure features DHFR inhibitors having a diaminoquinazoline scaffold.

  该披露涉及用于治疗真菌、细菌和寄生虫感染以及抑制真菌、细菌和寄生虫生长的组合物和方法。具体来说，这些组合物包括能够结合到二氢叶酸还原酶（DHFR）并抑制其功能的DHFR抑制剂，从而抑制DNA合成和减少细胞分裂。该披露涉及具有二氨基喹唑啉骨架的DHFR抑制剂。
• [EN] INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL<br/>[FR] INHIBITEURS DU CANAL À POTASSIUM DE LA MEDULLA EXTERNE DU REIN
  申请人：MERCK SHARP & DOHME

  公开号：WO2013039802A1

  公开（公告）日：2013-03-21

  This invention relates to compounds having structural Formula I: and pharmaceutically acceptable salts thereof which are inhibitors of the Renal Outer Medullary Potassium (ROMK) channel (Kir1.1). The compounds of Formula I are useful as diuretics and natriuretics and therefore are useful for the therapy and prophylaxis of disorders resulting from excessive salt and water retention, including cardiovascular diseases such as hypertension and chronic and acute heart failure.

  这项发明涉及具有结构式I的化合物及其药学上可接受的盐，这些化合物是肾外髓钾（ROMK）通道（Kir1.1）的抑制剂。式I的化合物可用作利尿剂和钠利尿剂，因此可用于治疗和预防由过多盐分和水分潴留引起的疾病，包括高血压和慢性和急性心力衰竭等心血管疾病。
• [EN] INHIBITORS OF THE BCL6 BTB DOMAIN PROTEIN-PROTEIN INTERACTION AND USES THEREOF<br/>[FR] INHIBITEURS DE L'INTERACTION PROTÉINE-PROTÉINE DU DOMAINE BCL6 BTB ET LEURS UTILISATIONS
  申请人：ONTARIO INSTITUTE FOR CANCER RES OICR

  公开号：WO2019153080A1

  公开（公告）日：2019-08-15

  The present application relates to compounds of Formula I (I) or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, to compositions comprising these compounds or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, and various uses in the treatment of diseases, disorders or conditions that are treatable by inhibiting interactions with BCL6 BTB, such as cancer.

  本申请涉及公式I（I）化合物或其药用可接受的盐、溶剂化合物和/或前药，包括含有这些化合物或药用可接受的盐、溶剂化合物和/或前药的组合物，以及在治疗可通过抑制与BCL6 BTB的相互作用可治疗的疾病、紊乱或状况中的各种用途，如癌症。
• Cyclic amine compounds
  申请人：Hasuoka Atsushi

  公开号：US20090042967A1

  公开（公告）日：2009-02-12

  The present invention relates to pharmaceutical agents which are agents for the prophylaxis or treatment of hypogonadism, male climacteric disorder, frailty, cachexia or osteoporosis; the pharmaceutical agents frailty suppressants, muscle strength enhancers, muscle increasing agents, cachexia suppressants, body weight decrease suppressants, agents for the prophylaxis or treatment of prostate hypertrophy, amyotrophy or muscle loss caused by a disease or an agent for reducing the prostate weight. The present invention also relates to methods for the prophylaxis or treatment of hypogonadism, male climacteric disorder, frailty, cachexia or osteoporosis in a mammal, which comprises administering an effective amount of the pharmaceutical agents of the present invention or a prodrug thereof; use of the pharmaceutical agents of the present invention or a prodrug thereof for the production of an agent for the prophylaxis or treatment of hypogonadism, male climacteric disorder, frailty, cachexia or osteoporosis; and the like.

  本发明涉及用于预防或治疗性腺功能减退症、男性更年期障碍、虚弱、消瘦或骨质疏松症的药物剂，其中包括虚弱抑制剂、肌肉力量增强剂、肌肉增长剂、消瘦抑制剂、体重减少抑制剂、用于预防或治疗前列腺肥大、肌萎缩或疾病引起的肌肉流失或降低前列腺重量的药物剂。本发明还涉及一种在哺乳动物中预防或治疗性腺功能减退症、男性更年期障碍、虚弱、消瘦或骨质疏松症的方法，包括向其投予本发明的药物剂或其前药的有效量；使用本发明的药物剂或其前药生产用于预防或治疗性腺功能减退症、男性更年期障碍、虚弱、消瘦或骨质疏松症的药物剂；等等。
• Synthesis and biological evaluation of novel selective androgen receptor modulators (SARMs). Part II: Optimization of 4-(pyrrolidin-1-yl)benzonitrile derivatives
  作者：Moriteru Asano、Takenori Hitaka、Takashi Imada、Masami Yamada、Megumi Morimoto、Hiromi Shinohara、Takahito Hara、Masuo Yamaoka、Takashi Santou、Masaharu Nakayama、Yumi Imai、Noriyuki Habuka、Jason Yano、Keith Wilson、Hisashi Fujita、Atsushi Hasuoka

  DOI：10.1016/j.bmcl.2017.03.038

  日期：2017.5

  tissue-selective androgen receptor modulators (SARMs), represented by a naphthalene derivative A. However, their pharmacokinetic (PK) profiles were poor due to low metabolic stability. To improve the PK profiles, we modified the hydroxypyrrolidine and benzonitrile substituents of 4-(pyrrolidin-1-yl)benzonitrile derivative B, which had a comparable potency as that of compound A. This optimization led us

  我们最近报道了一类新型的组织选择性雄激素受体调节剂（SARMs），以萘衍生物A为代表。但是，由于代谢稳定性低，它们的药代动力学（PK）状况很差。为了改善PK谱，我们修饰了4-（吡咯烷-1-基）苄腈衍生物B的羟基吡咯烷和苄腈取代基，其效力与化合物A相当。这种优化使我们进行了进一步的修饰，从而改善了代谢稳定性同时保持有效的雄激素激动活性。在合成的化合物中，（2S，3S）-2，3-二甲基-3-羟基吡咯烷衍生物1c表现出合适的PK曲线和改善的代谢稳定性。在体内研究中，化合物1c在提肛肌中显示出显着的功效，而没有增加前列腺的重量。